LEADER 05777nam 2201705z- 450 001 9910557546203321 005 20231214133607.0 035 $a(CKB)5400000000044145 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69451 035 $a(EXLCZ)995400000000044145 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNovel Biomarkers for Heart Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (420 p.) 311 $a3-03943-883-2 311 $a3-03943-884-0 330 $aCardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers. 606 $aMedicine$2bicssc 610 $adiet quality 610 $aceramides 610 $aobesity 610 $acardiovascular risk 610 $ahealthy eating index 610 $acarbohydrate antigen-125 610 $aheart failure 610 $ainflammatory marker 610 $aolder women 610 $abiomarker 610 $acardiometabolic disease 610 $aepicardial adipose tissue 610 $aepicardial fat 610 $aepicardial fat volume 610 $amicroRNA 610 $athyroid-stimulating hormone 610 $acardiometabolic risks 610 $ametabolic syndrome 610 $ahypertension 610 $avery low-density lipoprotein 610 $aSTIM1 610 $aSOCE 610 $aatrial myopathy 610 $aatrial fibrillation 610 $aejection fraction 610 $asoluble urokinase-type plasminogen activator receptor (suPAR) 610 $agrowth differentiation factor 15 (GDF-15) 610 $aheart-type fatty acid-binding protein (H-FABP) 610 $asoluble suppression of tumorigenicity 2 (sST2) 610 $aacute myocardial infarction 610 $abiomarkers 610 $acatestatin 610 $acoronary artery disease 610 $aheart failure decompensation 610 $aleft ventricular ejection fraction 610 $atroponin 610 $aNT-proBNP 610 $aNYHA functional class 610 $aGDF-15 610 $acardiovascular surgery 610 $aoperative risk 610 $amuscle wasting 610 $asarcopenia 610 $arenal dysfunction 610 $achronic kidney disease 610 $aaortic disease 610 $aaneurysm 610 $amiRNA 610 $aTGF-? pathway 610 $aKLF4 610 $asynthetic phenotype 610 $aaortic regurgitation 610 $aechocardiography 610 $amagnetic resonance imaging 610 $avena contracta area 610 $alongitudinal strain 610 $aT1 mapping 610 $aGDF8 610 $amyostatin 610 $aAMI 610 $aceruloplasmin 610 $aH-FABP 610 $aheart-type fatty acid-binding protein 610 $aFABP3 610 $afatty acid-binding protein 3 610 $aHF 610 $acardiac biomarkers 610 $acardiac magnetic resonance imaging 610 $aleft ventricular systolic function 610 $amagnetic resonance spectroscopy 610 $amyocardial triglyceride content 610 $acell adhesion molecule 610 $arepeated measurements 610 $apregnancy-associated plasma protein-A 610 $acohort studies 610 $acardiovascular diseases 610 $amitochondrial dysfunction 610 $acirculating cells 610 $aPBMCS 610 $aplatelets 610 $aoxidative stress 610 $areactive oxygen species (ROS) 610 $amitochondrial DNA (mtDNA) 610 $aherat failure 610 $aliver-type fatty-acid-binding protein 610 $along-term outcomes 610 $acardiac intensive care units 610 $aacute kidney injury 610 $amyocardial infarction 610 $aSTEMI 610 $acardiovascular events 610 $acardiovascular death 610 $arisk stratification 610 $asST2 610 $aPentraxin-3 610 $asudden cardiac death 610 $aventricular arrhythmia 610 $aventricular tachycardia 610 $achronic heart failure 610 $asaliva 610 $asalivary biomarkers 610 $aCKD 610 $aCVD 610 $aPPCI 610 $aleft ventricular adverse remodelling 610 $acirculating miRNAs 610 $aNAFLD 610 $aFramingham risk score 610 $arisk prediction 610 $asecondary prevention 610 $aprimary prevention 610 $aNAFLD fibrosis score 610 $aHFpEF 610 $aHFrEF 610 $asuPAR 615 7$aMedicine 700 $aLichtenauer$b Michael$4edt$01287943 702 $aLichtenauer$b Michael$4oth 906 $aBOOK 912 $a9910557546203321 996 $aNovel Biomarkers for Heart Disease$93020593 997 $aUNINA